288 related articles for article (PubMed ID: 6441963)
1. [Circulating immune complexes in patients with lymphoproliferative and myeloproliferative diseases].
Loni C; Ricci S; Azzarà A; Bertoncini G
Quad Sclavo Diagn; 1984 Jun; 20(2):193-202. PubMed ID: 6441963
[TBL] [Abstract][Full Text] [Related]
2. HL-A antigens and hematologic malignancy.
Miller WV
Arch Intern Med; 1974 Mar; 133(3):397-9. PubMed ID: 4521322
[No Abstract] [Full Text] [Related]
3. Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.
Carpentier NA; Lange GT; Fiere DM; Fournie GJ; Lambert PH; Miescher PA
J Clin Invest; 1977 Oct; 60(4):874-84. PubMed ID: 268330
[TBL] [Abstract][Full Text] [Related]
4. Increased circulating neutrophils with surface receptor activity for immunoglobulin G in polycythemia vera and myeloid metaplasia.
Gilbert HS; Goldberg R; Ward L
Blood; 1979 Jun; 53(6):1106-13. PubMed ID: 444652
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of circulating immune complexes in hemolymphopathies].
Delsignore R; Baroni MC; Mineo F; Crotti G; Butturini U
G Clin Med; 1984; 65(3-4):157-62. PubMed ID: 6588012
[No Abstract] [Full Text] [Related]
6. Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E
Cancer Res; 1986 Feb; 46(2):975-80. PubMed ID: 3455679
[TBL] [Abstract][Full Text] [Related]
7. Circulating immune complexes in patients with lymphomas and leukemias.
Patel GV; Gopal R; Nadkarni JJ
Neoplasma; 1984; 31(2):197-202. PubMed ID: 6585680
[TBL] [Abstract][Full Text] [Related]
8. [Current trends in therapy and prophylaxis of immunological disorders in malignant hemoreticulopathies].
Berceanu S; Gociu M
Stud Cercet Med Interna; 1969; 10(3):197-208. PubMed ID: 4186583
[No Abstract] [Full Text] [Related]
9. [Clinical significances of circulating immune complexes in hematologic disorders--detection by C1q deviation test and anti-antibody inhibition test].
Yasuda M; Nobunaga M; Sakai K; Motomura S; Ibayashi H; Kozuru M
Rinsho Ketsueki; 1983 Apr; 24(4):448-55. PubMed ID: 6604173
[No Abstract] [Full Text] [Related]
10. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
[TBL] [Abstract][Full Text] [Related]
11. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
12. Leukaemia and allied disorders. 3. Clinical findings in 200 personal cases.
Woodliff HJ
Med J Aust; 1972 Aug; 2(8):408-13. PubMed ID: 4628709
[No Abstract] [Full Text] [Related]
13. [Lymphocyte blastogenesis in vitro in leukemias and lymphomas of childhood].
Fabris C; De Sanctis C; Ponzone A
Minerva Pediatr; 1971 Feb; 23(5):194-8. PubMed ID: 5280413
[No Abstract] [Full Text] [Related]
14. Circulating immune complexes and the prognosis of acute myeloid leukemia.
Carpentier NA; Fiere DM; Schuh D; Lange GT; Lambert PH
N Engl J Med; 1982 Nov; 307(19):1174-80. PubMed ID: 6956807
[TBL] [Abstract][Full Text] [Related]
15. The role of the phagocyte in host-parasite interactions. 3. The phagocytic capabilities of leukocytes from myeloproliferative and other neoplastic disorders.
Sbarra AJ; Shirley W; Selvaraj RJ; McRipley RJ; Rosenbaum E
Cancer Res; 1965 Sep; 25(8):1199-206. PubMed ID: 5214691
[No Abstract] [Full Text] [Related]
16. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
17. [Immunological behavior of patients with malignant blood diseases].
Luca N
Stud Cercet Med Interna; 1973; 14(5):429-46. PubMed ID: 4202394
[No Abstract] [Full Text] [Related]
18. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
19. Immune complexes in myeloproliferative disorders.
Lewis CM; Pegrum GD
Lancet; 1977 Dec; 2(8049):1151-3. PubMed ID: 73061
[TBL] [Abstract][Full Text] [Related]
20. Circulating high molecular weight IgG fibronectin complexes in myeloproliferative disorders.
Baglin TP; Price SM; Boughton BJ
J Clin Pathol; 1990 Feb; 43(2):102-5. PubMed ID: 2318985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
